Full Title: rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
Status: Active, Recruiting
Age Range: 4 - 50 years
Locations: Royal Marsden Hospital, Clatterbridge Cancer Centre, University College London Hospital, Royal Victoria Infirmary, Bristol Royal Hospital for Children, St James's University Hospital, Alder Hey Children's Hospital, Churchill Hospital, Christie Hospital, John Radcliffe Hospital, The Queen Elizabeth Hospital, Sheffield Children's Hospital, Bristol Haematology And Oncology Centre, Queen's Medical Centre, Nottingham, Leicester Royal Infirmary, Royal Marsden Hospital Sutton, Weston Park Hospital, Freeman Hospital, Addenbrooke's Hospital, Southampton General Hospital, Royal Manchester Childrens Hospital, Nottingham City Hospital, Leeds General Infirmary, Birmingham Children's Hospital
Trial Lead: Dr Martin McCabe
Ewing sarcoma is treated with a combination of surgery, chemotherapy or radiotherapy, however, if it does not respond to these treatments, or comes back afterwards, there isn’t a standard treatment for patients to receive.
rEECur is an international trial, which aims to compare four different chemotherapy regimens to find out which is most effective and/or has fewest side effects. These four regimes form the four arms of the trial, which include:
TOPOTECAN AND CYCLOPHOSPHAMIDE (TC)
IRINOTECAN AND TEMOZOLOMIDE (IT)
GEMCITABINE AND DOCETAXEL (GD) - update: this arm has been dropped.
The trial is being run as it is not known which is the best treatment for this group of patients. The trial is randomised, meaning patients will be randomly assigned to a treatment arm by a computer. This is done so that neither the patient nor their doctor will be able to influence which treatment arm the patient is given and means that the results of the trial are not biased in any way.
If you would like any more information on clinical trials in general, please contact us at The Bone Cancer Research Trust. We are happy to answer your queries and, if required, pass on your details to the lead of this trial, Dr Martin McCabe. For more information on this trail, which may be useful to show your oncologist, you can contact the Cancer Research UK Clinical Trials Unit at the University of Birmingham here.
The study is supported by the European Commission’s FP7 health programme and The University of Birmingham.